UBS Knock-Out AMGN/ DE000UM2E397 /
15/11/2024 8:03:00 | Diferencia-0.020 | Bid8:03:00 | Ask8:03:00 | Subyacente | Precio de ejercicio | Fecha de expiración | Tipo de opción |
---|---|---|---|---|---|---|---|
1.400EUR | -1.41% | 1.400 Volumen de oferta: 20,000 |
1.440 Tamaño/ Volumen/ Formato de Ask: 20,000 |
Amgen Inc | 443.0396 USD | 31/12/2078 | Put |
GlobeNewswire
29/08
Great Place To Work Announces the 2024 Best Workplaces in Asia Representing 6.9 Million Employee Exp...
GlobeNewswire
28/08
Prevent Cancer Annual Gala to celebrate three decades of commitment to cancer prevention and early d...
GlobeNewswire
15/08
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
12/08
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/08
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
05/08
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
01/08
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
22/07
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
02/07
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página